National Animal Supplement Council’s Annual Conference Recap

This past week, Ahna Brutlag, DVM, MS, DABT, DABVT Director, Veterinary Services & Senior Veterinary Toxicologist, presented at the National Animal Supplement Council’s annual meeting. The virtual conference attracted a variety of attendees that have roles across the animal supplement industry. The agenda covered the topics of Science & Compliance, Sales & Marketing and Business Growth.

Dr. Brutlag presented during …

Industry Update on CBD Containing Dietary Supplements

Rick Kingston, PharmD
President, Regulatory and Scientific Affairs & Sr. Clinical Toxicologist

As most of us know the battle for FDA to allow CBD containing dietary supplements continues to rage.  Proponents of FDA action to allow CBD containing dietary supplements have been discouraged by FDA inaction in finding a path forward on that front.  Despite such slow movement in that …

Alphabet Soup: A Q&A about CBD with Pet Poison Helpline

By Tabatha Regehr, DVM
Associate Veterinarian &
Ahna Brutlag, DVM, MS, DABT, DABVT
Director of Veterinary Services

Cannabidiol, frequently referred to as “CBD”, is gaining in popularity and interest by pet owners and veterinary professionals alike. At Pet Poison Helpline, we get a lot of questions about the safety of CBD and the number of poison control consults regarding CBD …

SafetyCall Attends CHFA East

SafetyCall recently attended the Canadian Health Food Association’s (CHFA) eastern regulatory conference on September 12-13th and exhibited at the trade show September 14-15th, 2019. This was the first conference and trade show SafetyCall has attended with CHFA. Plans are already in the works to attend the western show in February 2020.

Much of the talk at the conference mirrored the …

Listen in as SafetyCall’s Rick Kingston Speaks at FDA Public Hearing

The FDA is seeking public comment regarding the availability of scientific data and information regarding Cannabis or Cannabis derived ingredients.  This has been a difficult topic for FDA considering the fact that such products are still classified as Schedule I substances at a Federal level. FDA is looking for scientific information to help them determine if there is a path